Health industries

  • Webcast
    21st Century Pharmaceutical Collaboration: The Value Convergence webcast - August 4, 2015

    7/17/15 | Health Research Institute

    This webcast presents findings from PwC's Health Research Institute report on the value of collaboration across the Health Industries sector.

  • Webcast
    Healthcare, Higher Education, and Nonprofit Series: Hot topics and technical updates impacting accounting and financial reporting - Webcast replay

    7/10/15 | Healthcare

    This webcast covers FASB standard setting developments that have occurred since our April webcast. We provide a refresher on accounting for various debt transactions as well as highlight new guidance in this area. We also cover developments related to FASB projects impacting not-for-profit entities, including the not-for-profit financial statement project.

  • Rx Marketplace Quarterly, Issue 6

    6/25/15 | Pharmaceuticals & life science

    The PwC Rx Marketplace Quarterly features a wide range of financial reporting developments, accounting and tax developments, regulatory updates and general industry trends impacting the pharmaceutical and life sciences industry.

  • Webcast
    Medical Cost Trend: Behind the Numbers 2016 - Webcast replay

    6/11/15 | Health Research Institute

    You are invited to watch a replay of our recorded webcast in which we present findings from the PwC Health Research Institute report on major trends in healthcare spending.

  • Medical Cost Trend: Behind the Numbers 2016

    6/9/15 | Health Research Institute

    Spending growth in the $2.9 trillion US health economy is expected to slow in 2016 as compared to 2015, but it will still outpace overall economic inflation. Stock prices, earnings reports and the customer base have increased and that means the industry is financially healthy. Affordable healthcare, however, remains out-of-reach for many consumers.

  • MoneyTree™ Life Sciences Report: Quarterly Q1 2015

    6/8/15 | Pharmaceuticals & life science

    US capital funding for the Life Sciences sector, which includes biotechnology and medical devices, increased 34% in value and 4% in volume during the first quarter of 2015. Venture capitalists invested $2.2 billion in 193 life sciences deals in first quarter 2015, compared with $1.6 billion in 186 deals during the same quarter of 2014. Also, significant to note, Biotech investment during the quarter was the strongest first quarter for biotech since the start of the MoneyTree data series in 1995.

  • In depth: Revenue standard is final – A comprehensive look at the new model (Health care services industry supplement)

    5/21/15 | Assurance services

    The FASB and IASB have issued their long-awaited converged standard on revenue recognition. How will you be affected? This industry-specific supplement to our In depth publication highlights some of the areas that could create the most significant challenges for health care services entities as they transition to the new revenue standard.

  • Money matters: Billing and payment for a New Health Economy

    5/18/15 | Health Research Institute

    The nation’s healthcare payment system is an artifact of an earlier age, focusing for decades on perfecting business-to-business functions. American consumers were patients, not purchasers.This is changing rapidly as individuals shoulder more of the cost of their own care. The healthcare billing and payment model must change as consumers demand systems that reflect the mobile, one-click reality of their lives.

  • US Health Services Deals Insights - Q1 2015 update

    5/18/15 | Transaction services

    The year is off to a rapid start with deal volume and disclosed value up 19% and 92%, respectively, in Q1 2015 compared to the first quarter of 2014. The most notable sectors were Managed Care, Behavioral Health and Rehabilitation, Physician Practice, and Private Equity while Home Health, Hospitals, and Labs, MRI, & Dialysis lagged behind.

  • Webcast
    Money matters: Billing and payment for a New Health Economy - Webcast replay

    5/15/15 | Health Research Institute

    In this webcast, we discuss the key findings from a new report on the future of healthcare payment and billing by PwC's Health Research Institute. To create a roadmap for a new consumer healthcare payments system, HRI commissioned a survey of 1,000 US adults and analyzed commercial claims from 34 million Americans in the Truven Health MarketScan® 2012 commercial claims database.

  • Pharmaceutical and Life Sciences Deals Insights Quarterly Q1 2015

    5/5/15 | Transaction services

    The pharmaceutical and life sciences (PLS) industry saw an astronomical increase in deal value, as compared to previous quarters and the entire year of 2014. In Q1, there were 35 deals completed, representing deal value of $166.3 billion, a value higher than 2014 total deals alone. In our market spotlight, we take a look at Japan, a country that is facing dynamic changes in the marketplace as medical costs are becoming an increasing focus of the Japanese Government. Additionally, as there are transformational shifts within the PLS and healthcare industries, PwC shares insights on the new era of the “New Health Economy”.

  • Webcast
    The broad impacts of PHI: Addressing the demands of customers and regulators webcast - Webcast replay

    5/4/15 | Risk Assurance

    This recorded webcast explains how to address the demands of customers and regulators around PHI, and discusses the latest privacy, security, and third party reporting trends impacting organizations that operate in the healthcare spectrum.

  • In brief
    In brief: FASB exposure draft proposes dramatic changes for not-for-profit (NFP) entities

    4/24/15 | Assurance services

    FASB exposure draft proposes significant changes to the not-for-profit (NFP) financial reporting model.

  • Rx Marketplace Quarterly, Issue 5

    3/24/15 | Pharmaceuticals & life science

    The PwC Rx Marketplace Quarterly features a wide range of financial reporting developments, accounting and tax developments, regulatory updates and general industry trends impacting the pharmaceutical and life sciences industry.

  • Quarter close
    The quarter close — First quarter 2015: Publication and new video perspectives

    3/16/15 | Assurance services

    The quarter close publication and video perspectives provide insight into the business and accounting impacts of declining oil and gas prices, recognizing the accounting implications of the Affordable Care Act, FASB, IASB and TRG developments related to implementing the new revenue standard, updates on FASB’s simplification proposals for stock-based compensation and income taxes, and more.

  • US Health Services Deals Insights - Analysis and trends in US health services activity 2014 and 2015 outlook

    3/9/15 | Healthcare

    In 2014, the pace of deal activity started strong and ended stronger. After the first quarter’s 9.2% increase in deal activity from the first quarter of 2013, we noted a lull in the second and third quarters’ deal pace. However, the fourth quarter of 2014 realized a 29% jump in deal volume as compared to the fourth quarter of 2013. This jump was enough to bring 2014’s total deal activity up 16.3% overall from 2013.

  • Top health industry issues of 2015

    2/23/15 | Health Research Institute

    As the health sector moves beyond the Affordable Care Act and onto consumer-centered, digitally enabled care, here are the top 10 issues dominating the agenda in 2015.

  • Webcast
    Navigating the FASB’s new consolidation standard - The impact on commercial and industrial companies webcast - On-demand (CPE-eligible)

    2/19/15

    Our webcast provides insight into the impact FASB’s new consolidation standard will have on commercial and industrial companies in the automotive, communications, entertainment & media, energy, healthcare, industrial products, pharmaceuticals, retail & consumer, transportation, technology, and utility industries. Watch a replay or participate in the on demand (CPE-eligible) version of this webcast.

  • Pharmaceutical and Life Sciences Deals Insights Quarterly Q4 2014

    2/17/15 | Transaction services

    Deal activity remained strong from the prior quarter as there was over $105 billion in announced and pending deals suggesting robust M&A activity may continue into 2015. As companies complete deals, integration becomes critical to achieving synergies. In this publication, we explore some of the methods being used to maximize synergies in the R&D function. Additionally this quarter's report's market spotlight looks at how Canada is essential to the development of future IP for companies within the industry. Canada has focused on becoming one of the most cost-effective countries for clinical development among the Group of Seven (G7) industrialized nations.

  • Rx Marketplace Quarterly, Issue 4

    12/24/14 | Pharmaceuticals & life science

    The PwC Rx Marketplace Quarterly features a wide range of financial reporting developments, accounting and tax developments, regulatory updates and general industry trends impacting the pharmaceutical and life sciences industry.

  • Healthcare provider: 2014 SEC comment letter trends

    12/8/14 | Health Research Institute

    To help registrants gain insight into the SEC’s current areas of interest, PwC analyzed comments released by the SEC staff to domestic large accelerated, accelerated and non-accelerated registrants within the healthcare provider industry during the two year period ended August 31, 2014.

  • Research and Development (R&D) Funding Arrangements

    11/18/14 | Pharmaceuticals & life science

    This Pharmaceutical and Life Sciences Alert focuses on Research and Development (R&D) Funding Arrangements.

  • Pharmaceutical and Life Sciences: 2014 SEC comment letter trends

    11/14/14 | Health Research Institute

    Our 2014 SEC comment letter trend compiles and analyzes the SEC staff’s comment letters issued over the past few years to registrants across different sectors within the Pharmaceutical and Life Sciences industry and provides highlights surrounding current hot topics and sample comments.

  • HR Innovation – Fall 2014

    10/29/14 | Human resource services

    HR Innovation offers advanced thinking about the challenges that should be uppermost on the minds and agendas of organizations and their Human Resources (HR) leaders.

  • Consumer Intelligence Series - The Wearable Future

    10/21/14 | Entertainment & media

    The Wearable Future, which looks at some of the strengths and opportunities for wearable tech—and the weaknesses and challenges that enterprising businesses must successfully navigate.

  • Change in timing for recording the Annual Pharmaceutical Fee

    10/15/14 | Pharmaceuticals & life science

    This Pharmaceutical and Life Sciences Alert focuses on the change in timing for the Annual Pharmaceutical Fee.

  • Rx Marketplace Quarterly, Issue 3

    10/2/14 | Pharmaceuticals & life science

    The PwC Rx Marketplace Quarterly features a wide range of financial reporting developments, accounting and tax developments, regulatory updates and general industry trends impacting the pharmaceutical and life sciences industry.

  • The rise of retail health insurance exchanges

    9/16/14 | Healthcare

    As health insurance becomes more consumer centric, employers must decide about exchanges: public, private, or none of the above. Early tremors in the market suggest a coming paradigm shift from a business-to-business model toward a business-to-consumer model of purchasing healthcare.

  • MoneyTree™ Life Sciences Report

    9/10/14 | Healthcare

    Biotech soars to record high: Investment in biotechnology was the highest since the start of the MoneyTree data series in 1995. Biotech and medical devices industries both see year-over-year double-digit growth in investments.

  • An HR perspective: Nothing but change for healthcare industry stakeholders

    8/5/14 | Human resource services

    Health care organizations today find themselves amid transformation on numerous fronts: everything from merging provider organizations to converging providers and payors to changing compensation models. Many of these changes are starting to reflect an Affordable Care Act America, along with more general shifts in the US healthcare industry—all of which yield implications for stakeholders across the board, including executives, employees, and physicians.

  • PwC's 2014 Health and Well-being Touchstone Survey results

    6/27/14 | Human resource services

    PwC is pleased to announce the availability of our 2014 Health and Well-being Touchstone Survey results. The 2014 survey data contains detailed benefits information provided by approximately 1,200 participating companies in 35 different industries across the nation.

  • Medical Cost Trend: Behind the numbers 2015

    6/26/14 | Health Research Institute

    The story of 2015 is a nuanced one. At first glance, the health sector appears to be reverting to historical patterns of bouncing back as the nation recovers from the economic doldrums. Whether spending more freely because of the improved economy or shopping with insurance provided through the Affordable Care Act, consumers triggered the first bump in growth in the first quarter of 2014. We expect that to continue through next year.

  • In depth: Revenue standard is final – A comprehensive look at the new model (Pharmaceutical & Life Sciences industry supplement)

    6/19/14 | Assurance services

    The FASB and IASB have issued their long-awaited converged standard on revenue recognition. How will you be affected? This industry-specific supplement to our In depth publication highlights some of the areas that could create the most significant challenges for Pharmaceutical & Life Sciences companies as they transition to the new revenue standard.

  • Webcast
    Revenue Recognition Webcast & Industry Supplement - Pharmaceutical and Life Sciences Companies

    6/11/14 | Pharmaceuticals & life science

    Join us for an expanded discussion on the specific impacts the new revenue recognition standard will have on the Pharmaceutical and Life Sciences industry and download our P&LS Industry Supplement.

  • IPR&D acquired in a business combination – How many pieces?

    5/21/14 | Pharmaceuticals & life science

    This Pharmaceutical and Life Sciences Alert focuses on in-process research and development (IPR&D) in acquisition accounting.

  • Potential impacts to Pharma and Life Sciences companies of the new accounting definition of an "investment company"

    4/10/14 | Pharmaceuticals & life science

    This Pharmaceutical and Life Sciences Alert focuses on the key accounting considerations when assessing whether an entity is an investment company under the new accounting definition and provides illustrative examples.

  • Rx Marketplace Quarterly Newsletter

    3/27/14 | Pharmaceuticals & life science

    The PwC Rx Marketplace Quarterly features a wide range of financial reporting developments, accounting and tax developments, regulatory updates and general industry trends impacting the pharmaceutical and life sciences industry. Each quarterly also shares strategies that companies can use to unlock divestiture value, as well as links to publications and online resources. In the spotlight in this issue is our summary of the IPO market, which has seen its most robust year since 2007. We cover key metrics for the past year, assess the industry’s top registrants, and offer a snapshot of IPO activity during the first two months of 2014.

  • Distinguishing a Business from an Asset or a Group of Assets

    1/16/14 | Pharmaceuticals & life science

    This Pharmaceutical and Life Sciences Industry GAAP Alert focuses on the key accounting considerations when making this determination and provides illustrative examples.

  • Video
    Healthcare costs and the Affordable Care Act

    12/10/13 | Assurance services

    PwC's Jay Seliber, Michael Thompson and Ken Stoler discuss the Affordable Care Act and accounting implications for retiree medical plans.

  • US GAAP: Issues and solutions for pharmaceuticals and life sciences industry

    11/20/13 | Pharmaceuticals & life science

    This publication highlights factors the industry should consider and provides guidance on the most pertinent accounting solutions under US GAAP. The solutions presented are meant to provide a framework for determining the appropriate accounting answer for general solutions.

  • M&A snapshot
    We’re acquiring a company with significant in-process research and development (IPR&D) activities. What's next? (M&A snapshot)

    4/23/13 | Assurance services

    This edition of Mergers & acquisitions — a snapshot provides an overview of the accounting rules and a glimpse into some of the issues companies face in the accounting and valuation of acquired IPR&D.